Guided Therapeutics EBITDA vs. Gross Profit

GTHP Stock  USD 0.18  0.01  5.88%   
Based on Guided Therapeutics' profitability indicators, Guided Therapeutics may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess Guided Therapeutics' ability to earn profits and add value for shareholders.
For Guided Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Guided Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Guided Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Guided Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Guided Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Risk vs Return Analysis.
Please note, there is a significant difference between Guided Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Guided Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Guided Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Guided Therapeutics Gross Profit vs. EBITDA Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Guided Therapeutics's current stock value. Our valuation model uses many indicators to compare Guided Therapeutics value to that of its competitors to determine the firm's financial worth.
Guided Therapeutics is one of the top stocks in ebitda category among its peers. It also is one of the top stocks in gross profit category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Guided Therapeutics' earnings, one of the primary drivers of an investment's value.

Guided Gross Profit vs. EBITDA

EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Guided Therapeutics

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
(837 K)
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.

Guided Therapeutics

Gross Profit

 = 

Revenue

-

Cost of Revenue

 = 
20 K
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.

Guided Gross Profit Comparison

Guided Therapeutics is currently under evaluation in gross profit category among its peers.

Guided Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Guided Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Guided Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Guided Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Guided Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Guided Therapeutics, Inc., a medical technology company, focuses on developing medical devices. Guided Therapeutics, Inc. was incorporated in 1992 and is based in Norcross, Georgia. Guided Therapeutics operates under Medical Devices classification in the United States and is traded on OTC Exchange. It employs 5 people.

Guided Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Guided Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Guided Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Guided Therapeutics' important profitability drivers and their relationship over time.

Use Guided Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Guided Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Guided Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Guided Therapeutics Pair Trading

Guided Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Guided Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Guided Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Guided Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Guided Therapeutics to buy it.
The correlation of Guided Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Guided Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Guided Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Guided Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Guided Therapeutics position

In addition to having Guided Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Toys Thematic Idea Now

Toys
Toys Theme
Companies producing and distributing toys and different gaming products for kids. The Toys theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Toys Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Guided OTC Stock Analysis

When running Guided Therapeutics' price analysis, check to measure Guided Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Guided Therapeutics is operating at the current time. Most of Guided Therapeutics' value examination focuses on studying past and present price action to predict the probability of Guided Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Guided Therapeutics' price. Additionally, you may evaluate how the addition of Guided Therapeutics to your portfolios can decrease your overall portfolio volatility.